[Executive Summary](index=1&type=section&id=Executive%20Summary) bioAffinity Technologies achieved significant Q2 2025 growth in CyPath Lung revenues and test volumes, alongside strategic milestones in product utility, pricing, logistics, capital raising, leadership, and intellectual property expansion [Q2 2025 Performance Overview](index=1&type=section&id=Q2%202025%20Performance%20Overview) bioAffinity Technologies reported significant growth in its CyPath Lung diagnostic product, with revenues increasing 62% year-over-year for the first six months of 2025, and test volumes also seeing a substantial rise, indicating growing clinical adoption - CyPath Lung revenues increased **62% year-over-year** for the six-month period ended June 30, 2025[3](index=3&type=chunk) - Completed CyPath Lung tests in July represented a **72% increase** over the previous monthly average for the first six months of 2025, including back-to-back record monthly sales in June and July[3](index=3&type=chunk) [Strategic and Operational Achievements](index=1&type=section&id=Strategic%20and%20Operational%20Achievements) The company achieved several strategic milestones, including demonstrating CyPath Lung's diagnostic utility through real-world case studies, increasing its list price, expanding logistics, completing a public offering, strengthening its leadership team, and expanding its global intellectual property portfolio - Released real-world case studies demonstrating the diagnostic utility of CyPath Lung, including successful detection of Stage 1A lung cancers[3](index=3&type=chunk) - Increased the list price of CyPath Lung to **$2,900**, aligning with private payer reimbursement strategies[3](index=3&type=chunk) - Expanded logistics capabilities through partnership with Cardinal Health™ OptiFreight Logistics, improving sample tracking and national delivery reliability[3](index=3&type=chunk) - Completed a **$3.25 million public offering** in May 2025 to provide working capital[3](index=3&type=chunk) - Appointed Dr. Gordon Downie, MD, PhD, as Chief Medical Officer, bringing over 30 years of clinical leadership[3](index=3&type=chunk) - Announced patent grants in the U.S., China, Canada, and Australia, expanding the global intellectual property portfolio for diagnostics and therapeutics[3](index=3&type=chunk) - Presented novel siRNA-based cancer therapy research at the 2025 RNA Therapeutics Conference[3](index=3&type=chunk) - President and CEO Maria Zannes appointed to the American Lung Association in Texas Leadership Board[3](index=3&type=chunk) [Management Discussion and Outlook](index=2&type=section&id=Management%20Commentary) Management commentary emphasizes the accelerated commercialization of CyPath Lung, strategic market expansion, strengthened financial and leadership foundations, and continued focus on product access and future innovation [CEO Commentary](index=2&type=section&id=CEO%20Commentary) CEO Maria Zannes highlighted the acceleration of CyPath Lung's commercialization, driven by increasing clinical adoption and validating real-world case studies, emphasizing the success of the Texas pilot marketing program, plans for expansion into new markets, and strategic steps taken to strengthen the financial foundation, leadership, and intellectual property, with a continued focus on expanding access, operational efficiency, and advancing next-generation diagnostics and therapeutics - Q2 results reflect continued acceleration of CyPath Lung commercialization strategy, with testing revenue up **62%** for the first half of the year, driven by increasing clinical adoption and physician-authored case studies[4](index=4&type=chunk) - The pilot marketing program in Texas demonstrated a sound and effective approach, preparing the company for expansion into additional key markets, including the Mid-Atlantic region and the Veterans Administration healthcare system[5](index=5&type=chunk) - Important steps were taken to strengthen the financial foundation, including a **$3.25 million public offering** and a strategic price adjustment for CyPath Lung, alongside enhanced national sample delivery capabilities through Cardinal Health OptiFreight® Logistics[6](index=6&type=chunk) - Expansion of the leadership team with Dr. Gordon Downie as Chief Medical Officer is shaping clinical direction, including advancement toward pivotal trials[7](index=7&type=chunk) - The intellectual property portfolio continues to grow with newly granted patents in the U.S., China, Canada, and Australia, strengthening diagnostic and therapeutic platforms globally[8](index=8&type=chunk) - Future focus remains on expanding access to CyPath Lung, delivering operational efficiency, and advancing next-generation diagnostics and therapeutics[9](index=9&type=chunk) [Second Quarter 2025 Financial Review](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Review) The second quarter 2025 financial review details a decrease in total revenue due to discontinued services, a reduction in operating expenses, an increased net loss driven by non-cash items, and a decline in cash reserves despite a successful public offering [Revenue Analysis](index=2&type=section&id=Revenue%20Analysis) Total revenue for Q2 2025 decreased significantly to $1.3 million from $2.4 million in Q2 2024, primarily due to the strategic discontinuation of unprofitable pathology services, however, CyPath Lung testing revenue for the first six months of 2025 increased by 62% year-over-year to $323,000, reflecting growth in physician adoption Net Revenue (Three Months Ended June 30) | Metric | Q2 2025 | Q2 2024 | | :----- | :------ | :------ | | Net Revenue | $1,269,483 | $2,397,652 | Net Revenue (Six Months Ended June 30) | Metric | H1 2025 | H1 2024 | | :----- | :------ | :------ | | Net Revenue | $3,123,080 | $4,804,043 | | CyPath Lung Testing Revenue | $323,000 | N/A | - The decrease in total revenue was primarily attributable to the Company's strategic decision to discontinue unprofitable pathology services and reallocate resources toward the commercialization of CyPath Lung[9](index=9&type=chunk) - CyPath Lung testing revenue for the six months ended June 30, 2025, increased approximately **62% year-over-year**, reflecting growth in physician adoption and an increase in total test results delivered[9](index=9&type=chunk) [Operating Expenses Analysis](index=3&type=section&id=Operating%20Expenses%20Analysis) Operating expenses for Q2 2025 decreased by 16% to $3.8 million, mainly due to lower direct costs from laboratory operations and reduced research and development expenses, partially offset by increased clinical development spending in support of pivotal trials Operating Expenses (Three Months Ended June 30) | Expense Category | Q2 2025 | Q2 2024 | Change | | :--------------- | :------ | :------ | :----- | | Total Operating Expenses | $3,785,043 | $4,485,450 | -15.62% | | Direct costs and expenses | $1,016,602 | $1,407,710 | -27.78% | | Research and development | $311,372 | $402,433 | -22.63% | | Clinical development | $129,279 | $51,462 | +151.21% | | Selling, general and administrative | $2,214,561 | $2,472,775 | -10.44% | | Depreciation and amortization | $113,229 | $151,070 | -25.05% | - The decrease in operating expenses was primarily due to lower direct costs related to laboratory operations and reduced research and development expenses[10](index=10&type=chunk) - Increased clinical development spending was in support of the Company's pivotal trial strategy[10](index=10&type=chunk) [Net Loss and Earnings Per Share](index=3&type=section&id=Net%20Loss%20and%20Earnings%20Per%20Share) The net loss for Q2 2025 increased to $4.1 million ($0.17 per share) from $2.1 million ($0.19 per share) in Q2 2024, primarily driven by a $1.5 million rise in non-cash expenses related to warrant remeasurement and public offering costs Net Loss and EPS (Three Months Ended June 30) | Metric | Q2 2025 | Q2 2024 | | :----- | :------ | :------ | | Net Loss | $(4,060,787) | $(2,110,279) | | Net Loss per Common Share (basic and diluted) | $(0.17) | $(0.19) | - The increase in net loss was primarily driven by a **$1.5 million increase** in non-cash expenses related to warrant remeasurement and offering costs associated with the May 2025 public offering[11](index=11&type=chunk) [Liquidity and Capital Resources](index=3&type=section&id=Liquidity%20and%20Capital%20Resources) Cash and cash equivalents decreased to $0.8 million as of June 30, 2025, from $1.1 million at the end of 2024, with the company successfully raising $3.25 million through a public offering in May 2025 to provide working capital Cash and Cash Equivalents | Date | Amount | | :--- | :----- | | June 30, 2025 | $802,835 | | December 31, 2024 | $1,105,291 | - bioAffinity Technologies raised aggregate gross proceeds of **$3.25 million** through a public offering in May 2025[3](index=3&type=chunk)[12](index=12&type=chunk) [Company Profile](index=3&type=section&id=About%20bioAffinity%20Technologies%2C%20Inc.) This section outlines bioAffinity Technologies' core business as a biotechnology company specializing in noninvasive early-stage lung cancer diagnostics and broad-spectrum cancer treatments, featuring its flagship product, CyPath Lung [Business Description](index=3&type=section&id=Business%20Description) bioAffinity Technologies is a biotechnology company focused on noninvasive diagnosis of early-stage lung cancer and other lung diseases, as well as developing broad-spectrum cancer treatments, with its flagship product, CyPath Lung, a highly sensitive, specific, and accurate noninvasive test for early-stage lung cancer, marketed as a Laboratory Developed Test (LDT) by its subsidiary, Precision Pathology Laboratory Services - bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments[13](index=13&type=chunk) - The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer[13](index=13&type=chunk) - CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies[13](index=13&type=chunk) [Condensed Consolidated Financial Statements](index=5&type=section&id=Condensed%20Consolidated%20Financial%20Statements) The condensed consolidated financial statements present a decrease in total assets, a significant increase in total liabilities due to warrant recognition, a shift to a stockholders' deficit, and an increased net loss for both the quarter and six-month periods, influenced by warrant fair value changes [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets decreased to $4.75 million from $6.51 million at December 31, 2024, total liabilities significantly increased to $6.89 million from $3.91 million, primarily due to the recognition of a warrant liability, and consequently, total stockholders' equity shifted from a positive $2.60 million to a deficit of $(2.14) million Balance Sheet Highlights | Metric | June 30, 2025 | December 31, 2024 | Change | | :-------------------------- | :------------ | :---------------- | :----- | | Total Assets | $4,751,075 | $6,513,667 | -27.06% | | Total Liabilities | $6,887,183 | $3,911,631 | +76.06% | | Total Stockholders' Equity (Deficit) | $(2,136,108) | $2,602,036 | -182.09% | | Warrant liability | $3,974,911 | — | N/A | - Cash and cash equivalents decreased from **$1,105,291** at December 31, 2024, to **$802,835** at June 30, 2025[18](index=18&type=chunk) [Unaudited Consolidated Statements of Operations](index=6&type=section&id=Unaudited%20Consolidated%20Statements%20of%20Operations) For the three months ended June 30, 2025, net revenue was $1.27 million, leading to a net loss of $4.06 million, and for the six months ended June 30, 2025, net revenue was $3.12 million, with a net loss of $6.72 million, where the significant increase in net loss for both periods was largely influenced by a $1.06 million change in the fair value of warrants Statements of Operations (Three Months Ended June 30) | Metric | 2025 | 2024 | Change | | :-------------------------------- | :----------- | :----------- | :----- | | Net Revenue | $1,269,483 | $2,397,652 | -47.05% | | Total Operating Expenses | $3,785,043 | $4,485,450 | -15.62% | | Loss from Operations | $(2,515,560) | $(2,087,798) | +20.49% | | Change in fair value of warrants issued | $(1,062,818) | — | N/A | | Net Loss | $(4,060,787) | $(2,110,279) | +92.43% | | Net Loss per Common Share | $(0.17) | $(0.19) | -10.53% | Statements of Operations (Six Months Ended June 30) | Metric | 2025 | 2024 | Change | | :-------------------------------- | :----------- | :----------- | :----- | | Net Revenue | $3,123,080 | $4,804,043 | -35.00% | | Total Operating Expenses | $8,265,779 | $8,837,071 | -6.50% | | Loss from Operations | $(5,142,699) | $(4,033,028) | +27.53% | | Change in fair value of warrants issued | $(1,062,818) | — | N/A | | Net Loss | $(6,721,204) | $(4,072,094) | +65.05% | | Net Loss per Common Share | $(0.20) | $(0.38) | -47.37% | [Additional Information](index=4&type=section&id=Additional%20Information) This section includes important disclaimers regarding forward-looking statements, highlighting inherent risks and the company's non-obligation to update them, along with essential contact information for communications and investor relations [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section contains forward-looking statements based on current estimates and assumptions, which are subject to various risks and uncertainties that could cause actual results to differ materially, with readers cautioned not to place undue reliance on these statements, and the company not undertaking any obligation to update them, except as required by applicable securities laws - Statements are based upon current estimates and assumptions and include statements regarding strategic actions, international patents, commercial growth, patient case studies, expanding access, and advancing new diagnostics[15](index=15&type=chunk) - These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations[15](index=15&type=chunk) - The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws[15](index=15&type=chunk) [Contacts](index=4&type=section&id=Contacts) Contact information is provided for bioAffinity Technologies' Director of Communications and for Investor Relations through RedChip Companies Inc - bioAffinity Technologies contact: Julie Anne Overton, Director of Communications (jao@bioaffinitytech.com)[16](index=16&type=chunk) - Investor Relations contact: Dave Gentry, RedChip Companies Inc. (1-800-RED-CHIP or 407-491-4498, BIAF@redchip.com)[16](index=16&type=chunk)

Core Insights - bioAffinity Technologies, Inc. (BIAF) reported a revenue decline of 22.9% year-over-year for Q1 2025, totaling $1.9 million, primarily due to changes in revenue contributions from various services [2] - Despite the revenue drop, the net loss per share improved to $0.16 from $0.20 in the previous year, although the absolute loss increased to $2.7 million from $1.9 million due to a higher share count [2] - The company's flagship diagnostic, CyPath Lung, experienced a significant sales increase of 276% year-over-year, indicating strong market acceptance and operational scaling [3] - Management is implementing strategic changes, including discontinuing low-margin services and cutting costs, expected to save approximately $3.8 million annually [4] - The company ended the quarter with $0.4 million in cash but has since raised $1.4 million through warrant exercises and $3.3 million via a public offering to support commercialization and clinical development [7] - bioAffinity received acceptance of a patent application for CyPath Lung from the Australian Patent Office, enhancing its international commercialization potential [9] Financial Performance - Revenues for Q1 2025 were $1.9 million, down from $2.4 million in Q1 2024 [2] - Operating expenses increased by 2.9% to $4.5 million, while direct costs declined by 13.1% to $1.4 million [2] - R&D expenses fell by 6.7% to $367,386, but clinical development expenses rose sharply from $48,960 to $138,353 [2] Strategic Initiatives - The company is focusing on commercial execution and operational changes to support CyPath Lung's growth [5] - Recent enhancements in test processing increased data acquisition throughput by 50% and reduced per-test costs by over 25% [6] - Management's strategic pivot aims to concentrate resources on high-margin diagnostics while improving overall profitability [4] Market Position and Future Outlook - The company did not provide forward-looking financial guidance but indicated a continued focus on expanding CyPath Lung's market presence [8] - The strong demand for CyPath Lung is supported by over 600 tests delivered in 2024, with continued momentum into 2025 [3]

[PART I FINANCIAL INFORMATION](index=7&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) This section presents the Company's unaudited condensed consolidated financial statements and management's discussion and analysis for the quarter ended March 31, 2025 [ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.](index=7&type=section&id=ITEM%201.%20CONDENSED%20CONSOLIDATED%20FINANCIAL%20STATEMENTS.) This section presents the unaudited condensed consolidated financial statements, including the balance sheets, statements of operations, statements of stockholders' equity, and statements of cash flows, along with their accompanying notes, for the periods ended March 31, 2025, and December 31, 2024 [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a snapshot of the Company's financial position, detailing assets, liabilities, and equity as of March 31, 2025, and December 31, 2024 Condensed Consolidated Balance Sheet Highlights ($) | Metric | March 31, 2025 | December 31, 2024 | | :-------------------------- | :------------- | :---------------- | | Cash and cash equivalents | $444,706 | $1,105,291 | | Total current assets | $1,863,782 | $2,695,098 | | Total assets | $5,547,283 | $6,513,667 | | Total current liabilities | $3,415,409 | $3,104,905 | | Total liabilities | $4,107,879 | $3,911,631 | | Total stockholders' equity | $1,439,404 | $2,602,036 | - The company's cash and cash equivalents decreased by approximately **60%** from **$1.11 million** at December 31, 2024, to **$0.44 million** at March 31, 2025[17](index=17&type=chunk) - Total stockholders' equity decreased by approximately **44.7%** from **$2.60 million** at December 31, 2024, to **$1.44 million** at March 31, 2025[17](index=17&type=chunk) [Unaudited Consolidated Statements of Operations](index=9&type=section&id=Unaudited%20Consolidated%20Statements%20of%20Operations) This section outlines the Company's financial performance, presenting net revenue, operating expenses, and net loss for the three months ended March 31, 2025 and 2024 Unaudited Consolidated Statements of Operations Highlights (Three Months Ended March 31) ($) | Metric | 2025 | 2024 | Change ($) | Change (%) | | :------------------------- | :------------ | :------------ | :------------ | :--------- | | Net Revenue | $1,853,597 | $2,406,391 | $(552,794) | (23.0)% | | Total operating expenses | $4,480,736 | $4,351,621 | $129,115 | 3.0% | | Loss from operations | $(2,627,139) | $(1,945,230) | $(681,909) | 35.1% | | Net loss | $(2,660,417) | $(1,961,815) | $(698,602) | 35.6% | | Net loss per common share | $(0.16) | $(0.20) | $0.04 | (20.0)% | - Net revenue decreased by **23%** primarily due to strategic actions to discontinue unprofitable pathology services and focus on high-margin services like CyPath Lung[98](index=98&type=chunk)[109](index=109&type=chunk) - Net loss increased by **35.6%** to **$2.66 million** in Q1 2025, compared to **$1.96 million** in Q1 2024, driven by higher operating expenses and a decrease in net revenue[19](index=19&type=chunk)[106](index=106&type=chunk) [Unaudited Consolidated Statements of Changes in Stockholders' Equity](index=10&type=section&id=Unaudited%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) This section details the changes in the Company's stockholders' equity, reflecting the impact of net loss, stock-based compensation, and warrant exercises for the three months ended March 31, 2025 Changes in Stockholders' Equity (Three Months Ended March 31, 2025) ($) | Item | Amount ($) | | :------------------------ | :--------- | | Balance at Dec 31, 2024 | 2,602,036 | | Stock-based compensation | 326,616 | | Exercise of stock warrants| 1,518,467 | | Offering costs | (347,298) | | Net loss | (2,660,417)| | Balance at Mar 31, 2025 | 1,439,404 | - Stockholders' equity decreased from **$2.60 million** at December 31, 2024, to **$1.44 million** at March 31, 2025, primarily due to a net loss of **$2.66 million**, partially offset by **$1.52 million** from warrant exercises and **$0.33 million** from stock-based compensation[21](index=21&type=chunk) [Unaudited Consolidated Statements of Cash Flows](index=11&type=section&id=Unaudited%20Consolidated%20Statements%20of%20Cash%20Flows) This section presents the Company's cash inflows and outflows from operating, investing, and financing activities for the three months ended March 31, 2025 and 2024 Unaudited Consolidated Statements of Cash Flows Highlights (Three Months Ended March 31) ($) | Cash Flow Activity | 2025 | 2024 | | :--------------------------- | :------------ | :------------ | | Net cash used in operating | $(1,641,775) | $(2,345,975) |\ | Net cash used in investing | $(50,786) | $(41,387) |\ | Net cash provided by financing | $1,031,976 | $2,018,957 |\ | Net decrease in cash | $(660,585) | $(368,405) |\ | Cash at end of period | $444,706 | $2,453,165 | - Net cash used in operating activities decreased by approximately **$0.7 million**, from **$2.35 million** in Q1 2024 to **$1.64 million** in Q1 2025, primarily due to changes in accounts receivables, accounts payable, and accrued expenses[23](index=23&type=chunk)[126](index=126&type=chunk) - Cash provided by financing activities decreased from **$2.02 million** in Q1 2024 to **$1.03 million** in Q1 2025, mainly due to lower net proceeds from financing activities compared to the prior year[23](index=23&type=chunk)[128](index=128&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and additional information supporting the unaudited condensed consolidated financial statements [Note 1. NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION](index=12&type=section&id=Note%201.%20NATURE%20OF%20OPERATIONS%2C%20ORGANIZATION%2C%20AND%20BASIS%20OF%20PRESENTATION) This note describes the Company's business, its organizational structure, and the fundamental principles underlying the financial statement presentation - bioAffinity Technologies focuses on noninvasive diagnosis of early-stage lung cancer and other lung diseases using its proprietary platform, CyPath Lung, which utilizes flow cytometry and AI-driven automated data analysis[26](index=26&type=chunk) - The Company acquired Precision Pathology Laboratory Services, LLC (PPLS) in August 2023, which operates a CAP-accredited, CLIA-certified clinical pathology laboratory and offers CyPath Lung[27](index=27&type=chunk)[93](index=93&type=chunk) - Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months due to significant losses and negative cash flows, with cash and cash equivalents of approximately **$0.4 million** at March 31, 2025[30](index=30&type=chunk) - A public offering completed on May 7, 2025, raised an additional **$3.25 million** in gross proceeds, but further capital will be needed to support future operations[30](index=30&type=chunk)[86](index=86&type=chunk) [Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES](index=12&type=section&id=Note%202.%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This note outlines the key accounting principles and methods used in the preparation of the Company's financial statements - The Company's revenue streams include patient service fees, histology service fees, and medical director fees, recognized upon completion of testing or service rendering[42](index=42&type=chunk) Net Revenue by Source (Three Months Ended March 31) ($) | Revenue Source | 2025 | 2024 | | :---------------------------------- | :------------ | :------------ | | Patient service fees | $1,570,382 | $2,149,049 | | Histology service fees | $263,754 | $237,972 | | Medical director fees | $16,588 | $16,058 | | Department of Defense observational studies | $— | $2,885 | | Other revenues | $2,873 | $427 | | **Total net revenue** | **$1,853,597**| **$2,406,391**| - Direct billing for CyPath Lung diagnostic test increased significantly from **$45,000** in Q1 2024 to **$169,000** in Q1 2025[44](index=44&type=chunk) Intangible Assets, Net (as of) ($) | Asset Category | March 31, 2025 | December 31, 2024 | | :------------------------ | :------------- | :---------------- | | Goodwill | $1,404,486 | $1,404,486 | | Trade names and trademarks| $150,000 | $150,000 | | Customer relationships | $700,000 | $700,000 | | Accumulated amortization | $(89,444) | $(74,861) | | **Intangible assets, net**| **$2,165,042** | **$2,179,625** | Net Revenues and Operating Expenses by Segment (Three Months Ended March 31) ($) | Segment | 2025 Net Revenues | 2024 Net Revenues | 2025 Operating Expenses | 2024 Operating Expenses | | :------------------------ | :---------------- | :---------------- | :---------------------- | :---------------------- | | Diagnostic R&D | $— | $2,885 | $(505,739) | $(442,599) | | Laboratory services | $1,853,597 | $2,403,506 | $(2,267,656) | $(2,736,999) | | General corporate activities| N/A | N/A | $(1,707,341) | $(1,172,023) | [Note 3. ACCOUNTS AND OTHER RECEIVABLES, NET](index=18&type=section&id=Note%203.%20ACCOUNTS%20AND%20OTHER%20RECEIVABLES%2C%20NET) This note details the composition of the Company's accounts and other receivables, net of allowances, as of the reporting dates Accounts and Other Receivables, Net (as of) ($) | Receivable Type | March 31, 2025 | December 31, 2024 | | :------------------------ | :------------- | :---------------- | | Patient service fees | $744,859 | $915,488 | | Histology service fees | $189,904 | $190,648 | | Medical director fees | $11,600 | $5,194 | | Other receivables | $17,381 | $27,874 | | **Total receivables, net**| **$963,744** | **$1,139,204** | [Note 4. PREPAID EXPENSES AND OTHER CURRENT ASSETS](index=18&type=section&id=Note%204.%20PREPAID%20EXPENSES%20AND%20OTHER%20CURRENT%20ASSETS) This note provides a breakdown of the Company's prepaid expenses and other current assets as of the reporting dates Prepaid Expenses and Other Current Assets (as of) ($) | Asset Type | March 31, 2025 | December 31, 2024 | | :------------------------ | :------------- | :---------------- | | Prepaid insurance | $160,756 | $248,364 | | Legal and professional | $15,787 | $27,448 | | Other | $240,007 | $147,183 | | **Total prepaid assets** | **$416,550** | **$422,995** | [Note 5. PROPERTY AND EQUIPMENT, NET](index=19&type=section&id=Note%205.%20PROPERTY%20AND%20EQUIPMENT%2C%20NET) This note presents the Company's property and equipment, net of accumulated depreciation, as of the reporting dates Property and Equipment, Net (as of) ($) | Asset Category | March 31, 2025 | December 31, 2024 | | :------------------------------ | :------------- | :---------------- | | Lab equipment | $679,995 | $662,747 | | Computers and software | $81,433 | $81,433 | | Leasehold improvements | $19,353 | $19,353 | | Vehicles | $181,640 | $148,103 | | Less: accumulated depreciation | $(580,012) | $(536,251) | | **Total property and equipment**| **$382,409** | **$375,385** | - Depreciation expense for the three months ended March 31, 2025, was **$43,763**, an increase from **$38,811** in the same period of 2024[58](index=58&type=chunk) [Note 6. ACCRUED EXPENSES](index=19&type=section&id=Note%206.%20ACCRUED%20EXPENSES) This note details the composition of the Company's accrued expenses as of the reporting dates Accrued Expenses (as of) ($) | Expense Type | March 31, 2025 | December 31, 2024 | | :------------------------ | :------------- | :---------------- | | Compensation | $932,208 | $1,079,839 | | Legal and professional | $107,064 | $98,477 | | Clinical | $287,258 | $160,371 | | Other | $44,205 | $60,035 | | **Total accrued expenses**| **$1,370,735** | **$1,398,722** | [Note 7. UNEARNED REVENUE](index=19&type=section&id=Note%207.%20UNEARNED%20REVENUE) This note explains the Company's unearned revenue balance related to an observational study with the U.S. Department of Defense - The Company had an unearned revenue balance of **$24,404** as of March 31, 2025, and December 31, 2024, related to an observational study of CyPath Lung with the U.S. Department of Defense, where performance obligations for 30 units were not yet complete[60](index=60&type=chunk) [Note 8. FAIR VALUE MEASUREMENTS](index=19&type=section&id=Note%208.%20FAIR%20VALUE%20MEASUREMENTS) This note describes the Company's methodology for fair value measurements of financial instruments using a three-level hierarchy - The Company classifies financial instruments into a three-level hierarchy based on the observability of inputs used in fair value measurement, with most short-term instruments carried at historical cost approximating fair value[61](index=61&type=chunk)[62](index=62&type=chunk) [Note 9. LEASES](index=19&type=section&id=Note%209.%20LEASES) This note provides details on the Company's operating and finance leases, including their terms, liabilities, and discount rates - The Company holds operating leases for real estate and office space (**2.3 to 5.4 years remaining**) and finance leases for lab equipment (**1.1 to 2.8 years remaining**), with imputed interest rates ranging from **7.43% to 8.07%**[63](index=63&type=chunk)[64](index=64&type=chunk)[65](index=65&type=chunk) Lease Liabilities and Terms (as of March 31, 2025) | Lease Type | Right-of-Use Asset, Net ($) | Current Liability ($) | Non-Current Liability ($) | Remaining Term (years) | Weighted-Average Discount Rate (%) | | :---------------------- | :---------------------- | :---------------- | :-------------------- | :--------------------- | :----------------------------- | | Operating leases | $431,746 | $130,342 | $308,415 | 3.60 | 7.38% | | Finance leases | $684,629 | $403,584 | $335,899 | 2.28 | 8.04% | [Note 10. NOTES PAYABLE](index=22&type=section&id=Note%2010.%20NOTES%20PAYABLE) This note outlines the Company's notes payable, including vehicle loans and short-term financing for insurance policies - The Company has vehicle notes payable, including a new loan for **$33,517** at **11.65%** interest (January 2025) and an existing loan for **$23,815** at **5.99%** interest (March 2024)[70](index=70&type=chunk)[71](index=71&type=chunk) - Short-term financing of approximately **$260,000** was obtained in September 2024 for director and officer insurance policies, with a **6.7%** fixed annual rate[72](index=72&type=chunk) [Note 11. COMMITMENTS AND CONTINGENCIES](index=22&type=section&id=Note%2011.%20COMMITMENTS%20AND%20CONTINGENCIES) This note addresses the Company's commitments and contingencies, including any material legal proceedings - The Company is not involved in any material pending legal proceedings[73](index=73&type=chunk) [Note 12. COMMON STOCK](index=22&type=section&id=Note%2012.%20COMMON%20STOCK) This note provides information on the Company's authorized, issued, and outstanding common stock as of March 31, 2025 - The Company has **100,000,000** authorized shares of Common Stock (**$0.007** par value) and **18,255,825** shares issued and outstanding as of March 31, 2025, including **430,474** unvested restricted stock awards[74](index=74&type=chunk) [Note 13. STOCK-BASED COMPENSATION](index=22&type=section&id=Note%2013.%20STOCK-BASED%20COMPENSATION) This note details the stock-based compensation expense and restricted stock award activity for the three months ended March 31, 2025 Stock-Based Compensation Expense (Three Months Ended March 31) ($) | Expense Category | 2025 | 2024 | | :------------------------ | :-------- | :-------- | | Research and development | $21,250 | $21,882 | | General and administrative| $305,366 | $260,731 | | **Total expense** | **$326,616**| **$282,613**| Restricted Stock Award Activity (as of March 31, 2025) (Number of RSAs) | Item | Number of RSAs | | :------------------------ | :------------- | | Balance at Dec 31, 2024 | 1,326,861 | | Granted | 253,398 | | Forfeited | (10,289) | | **Balance at Mar 31, 2025**| **1,569,970** | - During Q1 2025, the Company issued **243,109** restricted stock awards to employees, non-employees, and the board of directors, with vesting terms up to three years[79](index=79&type=chunk) [Note 14. WARRANTS](index=24&type=section&id=Note%2014.%20WARRANTS) This note provides information on the Company's outstanding warrants, including exercise activity and new issuances - As of March 31, 2025, the Company had **12,873,602** warrants outstanding with a weighted average exercise price of **$2.74**, expiring through February 2030[80](index=80&type=chunk) - During Q1 2025, **2,438,473** warrants were exercised, generating **$1,414,314** in proceeds, compared to no exercises in Q1 2024[80](index=80&type=chunk) - On February 25, 2025, a warrant inducement agreement led to the exercise of **2,438,473** existing warrants at a reduced price of **$0.58** per share, generating approximately **$1.4 million**, and the issuance of **2,926,166** new unregistered warrants at an exercise price of **$0.85**[81](index=81&type=chunk)[82](index=82&type=chunk)[102](index=102&type=chunk) [Note 15. SUBSEQUENT EVENTS](index=25&type=section&id=Note%2015.%20SUBSEQUENT%20EVENTS) This note discloses significant events that occurred after the balance sheet date but before the financial statements were issued - On May 7, 2025, the Company completed a public offering, raising **$3.25 million** in gross proceeds through the sale of common stock (including pre-funded warrants) and accompanying warrants with an exercise price of **$0.352** per share[86](index=86&type=chunk)[99](index=99&type=chunk) [ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.](index=26&type=section&id=ITEM%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS.) This section provides management's perspective on the Company's financial condition and results of operations for the three months ended March 31, 2025, compared to the same period in 2024, including an overview of the business, financial highlights, recent developments, and a discussion of liquidity and critical accounting estimates [Company Overview](index=26&type=section&id=Company%20Overview) This section introduces the Company's core business, its diagnostic platform, and its research initiatives - The Company develops noninvasive diagnostics for early-stage lung cancer and other lung diseases, utilizing flow cytometry and AI-driven machine learning for automated analysis[91](index=91&type=chunk) - CyPath Lung, the Company's diagnostic test, is offered through its wholly-owned subsidiary PPLS, which operates a CAP-accredited and CLIA-certified commercial laboratory[92](index=92&type=chunk)[93](index=93&type=chunk) - Through OncoSelect Therapeutics, LLC, the Company also conducts research into novel cancer therapeutic approaches and intends to seek strategic partners for development[94](index=94&type=chunk) [Current Year Financial Highlights](index=26&type=section&id=Current%20Year%20Financial%20Highlights) This section summarizes key financial performance indicators and significant events for the three months ended March 31, 2025 - Consolidated revenue decreased by approximately **23%** to **$1.9 million** for the three months ended March 31, 2025, compared to **$2.4 million** in the prior year, primarily due to strategic actions to discontinue unprofitable pathology services[98](index=98&type=chunk) - CyPath Lung testing revenue increased by approximately **275%** to **$169,000** for the three months ended March 31, 2025, up from **$45,000** in the comparable period of 2024, driven by an increase of approximately **200** total test results delivered[98](index=98&type=chunk) - The Company raised approximately **$1.4 million** in gross proceeds from equity transactions to fund operating activities during the quarter[98](index=98&type=chunk) [Recent Developments](index=28&type=section&id=Recent%20Developments) This section outlines significant events and strategic initiatives undertaken by the Company recently, impacting its operations and financial outlook - On May 8, 2025, the Company released 'CyPath Lung In Practice,' highlighting its clinical utility in accelerating diagnosis and preventing unnecessary invasive procedures[99](index=99&type=chunk) - On May 7, 2025, a public offering of securities was completed, generating **$3.25 million** in gross proceeds, consisting of common stock and warrants[99](index=99&type=chunk) - Effective April 1, 2025, the list price of CyPath Lung was increased from **$1,900** to **$2,900** to optimize reimbursement terms[100](index=100&type=chunk) - On March 7, 2025, the Company announced strategic actions to achieve **$3 to $4 million** in annual cost savings at PPLS by reducing labor costs, enhancing operational efficiency, and discontinuing unprofitable pathology services, while increasing resources for CyPath Lung sales[101](index=101&type=chunk) - On February 26, 2025, a warrant inducement agreement resulted in the exercise of **2,438,473** existing warrants for approximately **$1.4 million** in gross proceeds and the issuance of new unregistered common warrants[102](index=102&type=chunk) [Financial](index=28&type=section&id=Financial) This section discusses the Company's historical funding, current financial position, and future capital requirements - The Company has historically funded operations through private and public equity sales, with approximately **$46.0 million** in gross proceeds since inception[121](index=121&type=chunk) - As of March 31, 2025, the Company had cash and cash equivalents of **$0.4 million**, an accumulated deficit of approximately **$56.3 million**, and a working capital deficit of approximately **$1.6 million**[103](index=103&type=chunk)[104](index=104&type=chunk) - Despite recent financings, current cash and anticipated revenue are expected to support operations only through August 2025, leading management to conclude there is substantial doubt about the Company's ability to continue as a going concern[103](index=103&type=chunk) - The Company anticipates needing to raise additional capital through equity or debt sales, collaborative arrangements, or grants to fund future operations and product development[105](index=105&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) This section analyzes the Company's financial performance, detailing net loss, revenue, and operating expenses for the reporting periods [Net Loss](index=29&type=section&id=Net%20Loss) This section reports the Company's net loss for the three months ended March 31, 2025, compared to the prior year - Net loss for the three months ended March 31, 2025, was approximately **$2.7 million**, an increase from approximately **$2.0 million** for the same period in 2024[106](index=106&type=chunk) [Revenue](index=29&type=section&id=Revenue) This section provides a detailed breakdown and analysis of the Company's net revenue by source for the reporting periods Net Revenue Breakdown (Three Months Ended March 31) ($) | Revenue Source | 2025 | 2024 | Change ($) | Change (%) | | :---------------------------------- | :------------ | :------------ | :------------ | :--------- | | Patient service fees | $1,570,382 | $2,149,049 | $(578,667) | (26.9)% | | Histology service fees | $263,754 | $237,972 | $25,782 | 10.8% | | Medical director fees | $16,588 | $16,058 | $530 | 3.3% | | Department of Defense observational studies | $— | $2,885 | $(2,885) | (100.0)% | | Other revenues | $2,873 | $427 | $2,446 | 572.8% | | **Total net revenue** | **$1,853,597**| **$2,406,391**| **$(552,794)**| **(23.0)%**| - The decrease in total net revenue is primarily attributed to discontinuing certain unprofitable pathology services to focus on high-margin services like CyPath Lung[109](index=109&type=chunk) [Operating Expenses](index=29&type=section&id=Operating%20Expenses) This section analyzes the Company's operating expenses by category, highlighting changes and their underlying drivers Operating Expenses (Three Months Ended March 31) ($) | Expense Category | 2025 | 2024 | Change ($) | Change (%) | | :-------------------------------- | :------------ | :------------ | :------------ | :--------- | | Direct costs and expenses | $1,367,860 | $1,573,441 | $(205,581) | (13)% | | Research and development | $367,386 | $393,639 | $(26,253) | (7)% | | Clinical development | $138,353 | $48,960 | $89,393 | 183% | | Selling, general and administrative | $2,452,549 | $2,185,944 | $266,605 | 12% | | Depreciation and amortization | $154,588 | $149,637 | $4,951 | 3% | | **Total operating expenses** | **$4,480,736**| **$4,351,621**| **$129,115** | **3%** | - Direct costs and expenses decreased by **13%** due to strategic actions in March 2025 to streamline operations and reduce lab-related costs[111](index=111&type=chunk) - Clinical development expenses increased by **183%** due to higher professional fees related to managing the pivotal clinical trial strategy[114](index=114&type=chunk) - Selling, general and administrative expenses increased by **12%** due to additional personnel and support services to drive CyPath Lung sales growth[116](index=116&type=chunk) [Other Income (Expense)](index=30&type=section&id=Other%20Income%20%28Expense%29) This section details the Company's non-operating income and expenses, including interest and other miscellaneous items Other Income (Expense) (Three Months Ended March 31) ($) | Category | 2025 | 2024 | Change ($) | Change (%) | | :---------------------------- | :------------ | :------------ | :------------ | :--------- | | Interest (expense) income, net| $(14,493) | $(17,423) | $2,480 | (14)% | | Other income (expense), net | $(9,640) | $4,510 | $(14,150) | (314)% | | **Total other (expense) income**| **$(24,583)** | **$(12,913)** | **$(11,670)** | **90%** | - Total other expense increased by **90%** primarily due to a decrease in other income (expense) of **$14,150**, mainly attributable to property taxes[118](index=118&type=chunk)[120](index=120&type=chunk) [Liquidity, Capital Resources, and Going Concern](index=30&type=section&id=Liquidity%2C%20Capital%20Resources%2C%20and%20Going%20Concern) This section assesses the Company's ability to meet its short-term and long-term obligations, its capital-raising efforts, and its going concern status - The Company has incurred significant losses since its inception in 2014, with net losses of **$2.7 million** and **$2.0 million** for the three months ended March 31, 2025 and 2024, respectively, and an accumulated deficit of approximately **$56.3 million** as of March 31, 2025[122](index=122&type=chunk) - Despite recent financings totaling **$4.65 million** in gross proceeds (February and May 2025), the Company's cash and anticipated revenue are only expected to support operations through August 2025[122](index=122&type=chunk)[123](index=123&type=chunk) - Management concludes there is substantial doubt about the Company's ability to continue as a going concern for at least twelve months, necessitating further capital raises through equity, debt, or strategic relationships[123](index=123&type=chunk) [Summary Statements of Cash Flows](index=31&type=section&id=Summary%20Statements%20of%20Cash%20Flows) This section provides a summary of the Company's cash flow activities, categorized into operating, investing, and financing [Net Cash Used in Operating Activities](index=32&type=section&id=Net%20Cash%20Used%20in%20Operating%20Activities) This section analyzes the cash flows generated or used by the Company's primary business operations - Net cash used in operating activities decreased by approximately **$0.7 million** to **$1.6 million** for the three months ended March 31, 2025, compared to **$2.3 million** in the prior year, primarily due to a decrease in patient accounts receivables and an increase in accounts payable and accrued expenses[126](index=126&type=chunk) [Net Cash Used in Investing Activities](index=32&type=section&id=Net%20Cash%20Used%20in%20Investing%20Activities) This section details the cash flows related to the acquisition and disposal of long-term assets - Net cash used in investing activities was approximately **$0.05 million** for the three months ended March 31, 2025, mainly for the purchase of computer and laboratory equipment, a slight increase from **$0.04 million** in the prior year[127](index=127&type=chunk) [Net Cash Provided by Financing Activities](index=32&type=section&id=Net%20Cash%20Provided%20by%20Financing%20Activities) This section outlines the cash flows from debt and equity transactions, impacting the Company's capital structure - Net cash provided by financing activities decreased to approximately **$1.0 million** for the three months ended March 31, 2025, from **$2.0 million** in the prior year, primarily due to lower net proceeds from financing activities in February 2025 (**$1.4 million**) compared to March 2024 (**$2.5 million**)[128](index=128&type=chunk) [Contractual Obligations and Commitments](index=32&type=section&id=Contractual%20Obligations%20and%20Commitments) This section discusses the Company's contractual obligations and commitments, noting that non-cancelable obligations are not material - The Company's contracts with third-party organizations for clinical trials and other services generally include termination clauses, and thus, non-cancelable obligations are not considered material[129](index=129&type=chunk) [Critical Accounting Estimates](index=32&type=section&id=Critical%20Accounting%20Estimates) This section highlights the accounting estimates that require significant judgment and can materially impact the financial statements - Key accounting estimates include patient fee revenues (requiring judgment for contractual allowances and implicit price concessions), patient fee receivables and credit losses (assessing portfolio risk and historical collection data), discount rate for finance leased equipment (using a benchmarked incremental borrowing rate), stock-based compensation (using Black-Scholes model with management's best estimates), accounting for income taxes (asset and liability approach with valuation allowance assessment), and going concern evaluation (assessing future cash sources and uses)[130](index=130&type=chunk)[131](index=131&type=chunk)[132](index=132&type=chunk)[133](index=133&type=chunk)[134](index=134&type=chunk)[135](index=135&type=chunk)[137](index=137&type=chunk) [Off-Balance Sheet Arrangements](index=34&type=section&id=Off-Balance%20Sheet%20Arrangements) This section confirms the absence of off-balance sheet arrangements that could materially affect the Company's financial position - The Company does not engage in transactions that generate relationships with unconsolidated entities or financial partnerships, and therefore had no off-balance sheet arrangements during the periods presented[138](index=138&type=chunk) [Emerging Growth Company Status](index=34&type=section&id=Emerging%20Growth%20Company%20Status) This section clarifies the Company's status as an emerging growth and smaller reporting company, detailing its reduced reporting requirements - The Company is classified as both an 'emerging growth company' and a 'smaller reporting company,' which subjects it to reduced public company reporting requirements under the Exchange Act[139](index=139&type=chunk) [ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.](index=34&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK.) As a smaller reporting company, bioAffinity Technologies is not required to provide quantitative and qualitative disclosures about market risk - The Company is exempt from providing market risk disclosures under Item 305(e) of Regulation S-K due to its status as a smaller reporting company[140](index=140&type=chunk) [ITEM 4. CONTROLS AND PROCEDURES.](index=34&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES.) This section details the evaluation of the Company's disclosure controls and procedures and reports on any changes in internal control over financial reporting [Evaluation of Disclosure Controls and Procedures](index=34&type=section&id=Evaluation%20of%20Disclosure%20Controls%20and%20Procedures) This section reports on the effectiveness of the Company's disclosure controls and procedures as assessed by management - As of March 31, 2025, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective in ensuring timely and accurate reporting[141](index=141&type=chunk) [Changes in Internal Control over Financial Reporting](index=34&type=section&id=Changes%20in%20Internal%20Control%20over%20Financial%20Reporting) This section reports on any material changes in the Company's internal control over financial reporting during the quarter - There were no changes in the Company's internal control over financial reporting during the three months ended March 31, 2025, that materially affected or are reasonably likely to materially affect internal control over financial reporting[142](index=142&type=chunk) [PART II OTHER INFORMATION](index=35&type=section&id=PART%20II%20OTHER%20INFORMATION) This section provides additional information not covered in the financial statements, including legal proceedings, risk factors, and other disclosures [ITEM 1. LEGAL PROCEEDINGS.](index=35&type=section&id=ITEM%201.%20LEGAL%20PROCEEDINGS.) This section states that the Company is not currently involved in any material legal proceedings - The Company has no material pending legal proceedings that are expected to have a material adverse impact on its financial position or results of operations[144](index=144&type=chunk) [ITEM 1A. RISK FACTORS.](index=35&type=section&id=ITEM%201A.%20RISK%20FACTORS.) This section updates the risk factors previously disclosed in the 2024 Form 10-K, emphasizing risks related to the Company's financial position, ability to obtain additional capital, Nasdaq listing compliance, and the concentration of common stock ownership by management - The Company's business plan relies heavily on its ability to obtain additional capital and financing, and failure to do so could lead to curtailment or cessation of operations[146](index=146&type=chunk)[150](index=150&type=chunk) - There is substantial doubt about the Company's ability to continue as a going concern, requiring additional capital to fund operations beyond August 2025[150](index=150&type=chunk) - The Company is at risk of de-listing from The Nasdaq Capital Market due to not meeting the minimum bid price requirement and having stockholders' equity below the required **$2.5 million**[153](index=153&type=chunk)[155](index=155&type=chunk) - Management collectively owns approximately **26%** of the Company's voting power, which could influence corporate decisions and potentially deter changes of control[157](index=157&type=chunk) [ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.](index=38&type=section&id=ITEM%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS.) This section confirms that the Company did not engage in any unregistered sales of equity securities during the quarter ended March 31, 2025, beyond what was previously disclosed - No unregistered sales of equity securities occurred during the quarter ended March 31, 2025, other than those previously disclosed[159](index=159&type=chunk) [ITEM 3. DEFAULTS UPON SENIOR SECURITIES.](index=38&type=section&id=ITEM%203.%20DEFAULTS%20UPON%20SENIOR%20SECURITIES.) This section states that there are no defaults upon senior securities to report - This item is not applicable to the Company for the reporting period[160](index=160&type=chunk) [ITEM 4. MINE SAFETY DISCLOSURE.](index=38&type=section&id=ITEM%204.%20MINE%20SAFETY%20DISCLOSURE.) This section indicates that mine safety disclosure is not applicable to the Company - This item is not applicable to the Company for the reporting period[161](index=161&type=chunk) [ITEM 5. OTHER INFORMATION.](index=38&type=section&id=ITEM%205.%20OTHER%20INFORMATION.) This section reports on Rule 10b5-1 trading arrangements by directors and officers - No director or officer adopted or terminated a 'Rule 10b5-1 trading arrangement' or 'non-Rule 10b5-1 trading arrangement' during the three months ended March 31, 2025[162](index=162&type=chunk) [ITEM 6. EXHIBITS.](index=39&type=section&id=ITEM%206.%20EXHIBITS.) This section provides a list of exhibits filed as part of this Quarterly Report on Form 10-Q - The report includes various exhibits such as the Certificate of Incorporation, Amended and Restated Bylaws, forms of warrants, employment agreements, and certifications under the Sarbanes-Oxley Act[164](index=164&type=chunk) [SIGNATURES](index=40&type=section&id=SIGNATURES) This section contains the signatures of the Company's authorized officers, certifying the report - The report is signed by Maria Zannes, Chief Executive Officer, President, Founder, and Director, and J. Michael Edwards, Vice President and Chief Financial Officer, on May 15, 2025[168](index=168&type=chunk)

[Executive Summary & Business Update](index=1&type=section&id=Executive%20Summary%20%26%20Business%20Update) [Company Overview](index=1&type=section&id=Company%20Overview) bioAffinity Technologies, Inc. is a biotechnology company focused on developing accurate, noninvasive tests for early-stage lung cancer and other lung diseases, with its primary product being CyPath Lung - bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive tests for early-stage lung cancer and other lung diseases, as well as broad-spectrum cancer treatments[2](index=2&type=chunk)[13](index=13&type=chunk) - The company's first product, CyPath Lung, is a noninvasive test for early-stage lung cancer, marketed as a Laboratory Developed Test (LDT) by its subsidiary, Precision Pathology Laboratory Services[13](index=13&type=chunk) [Key Highlights & Management Commentary](index=1&type=section&id=Key%20Highlights%20%26%20Management%20Commentary) The company reported strong momentum in Q1 2025, driven by significant year-over-year growth in CyPathLung sales and strategic actions to streamline operations and reduce costs, while also expanding its commercial footprint and intellectual property [Operational & Strategic Achievements](index=1&type=section&id=Operational%20%26%20Strategic%20Achievements) Key operational achievements include a substantial increase in CyPathLung sales, successful beta launch results, significant cost reduction initiatives, and advancements in intellectual property and processing efficiency CyPathLung Sales Growth (Q1 2025 vs. Q1 2024) | Metric | Q1 2025 | YoY Change | | :--------------- | :------ | :--------- | | CyPathLung Sales | N/A | **+276%** | - Strategic actions implemented in March 2025, including streamlining operations, reducing labor costs, and discontinuing suboptimal pathology services, are expected to reduce annual costs by approximately **$3.8 million**[5](index=5&type=chunk)[6](index=6&type=chunk) - The company received acceptance of a new patent application from the Australian Patent Office, enhancing international IP protection and global commercialization potential for CyPathLung[6](index=6&type=chunk) - Subsequent to the first quarter, improvements to CyPath Lung processing increased data acquisition throughput by **50%** and reduced unit cost by over **25%**[6](index=6&type=chunk)[7](index=7&type=chunk) [Management Outlook](index=1&type=section&id=Management%20Outlook) CEO Maria Zannes emphasized the growing demand for CyPathLung, the successful execution of the company's strategy focusing on high-value services and operational efficiency, and a commitment to expanding access and developing new diagnostics - CEO Maria Zannes highlighted strong momentum in Q1 2025, attributing it to growing demand for CyPathLung and successful execution of a strategy focused on high-value services and operational efficiency[4](index=4&type=chunk) - The company is committed to expanding access to CyPath Lung for patients at risk of lung cancer and advancing new diagnostics for diseases like COPD and asthma[8](index=8&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) [First Quarter 2025 Financial Results Overview](index=2&type=section&id=First%20Quarter%202025%20Financial%20Results%20Overview) bioAffinity Technologies reported $1.9 million in revenue for Q1 2025, a decrease from the prior year, alongside an increase in operating expenses and a higher net loss. The company's cash position decreased, though subsequent financing activities raised additional capital Q1 2025 vs Q1 2024 Financial Summary | Metric | Q1 2025 | Q1 2024 | YoY Change | | :------------------------------------ | :------------- | :------------- | :--------- | | Net Revenue | **$1.9 million** | $2.4 million | **-20.8%** | | Operating Expenses | **$4.5 million** | $4.4 million | **+2.3%** | | Net Loss | **$(2.7) million** | $(2.0) million | **+35.0%** | | Net Loss Per Share (basic & diluted) | **$(0.16)** | $(0.20) | **-20.0%** | | Cash and Cash Equivalents (as of period end) | **$0.4 million** (Mar 31, 2025) | $1.1 million (Dec 31, 2024) | **-63.6%** | - Subsequent to the end of 2024, bioAffinity Technologies raised gross proceeds of **$1.4 million** through warrant exercises in February 2025 and **$3.3 million** in a public offering in May 2025[12](index=12&type=chunk) [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, the company's total assets decreased to $5.5 million from $6.5 million at December 31, 2024, primarily driven by a reduction in cash and cash equivalents. Total liabilities increased, while total stockholders' equity decreased significantly Selected Balance Sheet Items (March 31, 2025 vs. December 31, 2024) | Item | March 31, 2025 | December 31, 2024 | | :------------------------ | :------------- | :---------------- | | Cash and cash equivalents | **$444,706** | $1,105,291 | | Total current assets | **$1,863,782** | $2,695,098 | | Total assets | **$5,547,283** | $6,513,667 | | Total current liabilities | **$3,415,409** | $3,104,905 | | Total liabilities | **$4,107,879** | $3,911,631 | | Total stockholders' equity| **$1,439,404** | $2,602,036 | [Unaudited Condensed Consolidated Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) For Q1 2025, net revenue was $1.85 million, a decrease from Q1 2024. Operating expenses totaled $4.48 million, with direct costs decreasing due to strategic actions, while clinical development and selling, general and administrative expenses increased, leading to a net loss of $2.66 million Q1 2025 vs Q1 2024 Operating Expenses Breakdown | Expense Category | Q1 2025 | Q1 2024 | YoY Change | | :-------------------------------- | :----------- | :----------- | :--------- | | Direct costs and expenses | **$1,367,860** | $1,573,441 | **-13.0%** | | Research and development | **$367,386** | $393,639 | **-6.7%** | | Clinical development | **$138,353** | $48,960 | **+182.6%** | | Selling, general and administrative | **$2,452,549** | $2,185,944 | **+12.2%** | | Depreciation and amortization | **$154,588** | $149,637 | **+3.3%** | - Direct costs and expenses decreased **13%** year-over-year, primarily due to targeted strategic actions implemented in March 2025[10](index=10&type=chunk) - Selling, general and administrative expenses increased, mainly driven by higher employee compensation related to administrative and sales functions to scale the commercialization of CyPath Lung[11](index=11&type=chunk) [Additional Information](index=3&type=section&id=Additional%20Information) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) This section provides a standard disclaimer regarding forward-looking statements, highlighting that future results may differ materially due to various risks and uncertainties - The press release contains forward-looking statements, which are based on current estimates and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations[14](index=14&type=chunk) [Contacts](index=3&type=section&id=Contacts) Contact information for media and investor relations is provided for inquiries related to bioAffinity Technologies - Contact information for bioAffinity Technologies' Director of Communications (Julie Anne Overton) and Investor Relations (Dave Gentry of RedChip Companies Inc.) is provided[15](index=15&type=chunk)

Core Viewpoint - bioAffinity Technologies, Inc. has successfully closed a best efforts offering of securities, raising a total of $3.25 million before expenses [1]. Group 1: Offering Details - The offering included 10,156,250 shares of Common Stock and warrants to purchase up to 15,234,375 shares of Common Stock, with a combined public offering price of $0.32 per share or pre-funded warrant [2]. - WallachBeth Capital, LLC served as the sole placement agent for this offering [2]. Group 2: Company Background - WallachBeth Capital LLC provides a wide range of capital markets and investment banking services, particularly to the healthcare sector, facilitating connections between corporate clients and leading institutions [5].

Shares of bioAffinity Technologies, Inc. (BIAF) have surged 160.9% since the company reported its financial results for the year ended Dec. 31, 2024. In stark contrast, the S&P 500 Index declined 8.9% during the same period. Over the past month, BIAF stock notched an impressive gain of 89.3%, outperforming the S&P 500’s 9.7% slide.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Revenue Growth and Profitability MetricsbioAffinity reported record revenues of $9.4 million for 2024, marki ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. (Exact name of registrant as specified in its charter) Delaware 46-5211056 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217 (Address of principal executive offices) (Zip Code) (210) 698-5334 OR ...

Revenue Growth - Record revenue of $9.4 million in 2024, a 270% increase from $2.5 million in 2023[3] - Net revenue for 2024 reached $9,362,022, a significant increase from $2,532,499 in 2023, representing a growth of approximately 269%[21] - Anticipated total revenue for 2025 is projected to be between $6 million to $8 million, including $1 to $2 million from CyPath lung tests[4] Product Adoption - CyPath® Lung orders increased by approximately 1,400% compared to full-year 2023, indicating strong physician adoption[3] - The number of signed physician offices grew by over 300% in 2024, positioning the company for continued growth in 2025[3] Operating Expenses - Operating expenses for 2024 totaled $18.3 million, up from $10.5 million in 2023, reflecting expanded operations and increased marketing efforts[11] - Total operating expenses for 2024 were $18,315,467, up from $10,505,727 in 2023, indicating a rise of about 74%[21] - Selling, general and administrative expenses rose to $9,943,473 in 2024 from $6,790,654 in 2023, marking an increase of approximately 46%[21] Net Loss - Net loss for 2024 was $9.0 million, or $0.75 per share, compared to a net loss of $7.9 million, or $0.91 per share, in 2023[13] - Loss from operations increased to $(8,953,445) in 2024 compared to $(7,973,228) in 2023, reflecting a deterioration of approximately 12%[21] - Net loss for 2024 was $(9,039,831), compared to $(7,937,011) in 2023, which is an increase of about 14%[21] - Net loss per common share improved to $(0.75) in 2024 from $(0.91) in 2023, showing a reduction in loss per share by approximately 17%[21] Cash Position - Cash and cash equivalents decreased to $1.1 million as of December 31, 2024, down from $2.8 million in 2023[14] Research and Development - Research and development expenses remained relatively stable at $1,461,227 in 2024 compared to $1,467,936 in 2023, showing a slight decrease of about 0.5%[21] Clinical Trials and Patents - The FDA pivotal study protocol has been submitted for a clinical trial expected to enroll approximately 3,500 patients in 2025[8] - The company received a patent from the Japan Patent Office for its method using flow cytometry to predict lung disease[7] Economic Impact - The economic validation study indicated potential savings of $379 million for Medicare patients and $895 million for private insurance patients if CyPath® Lung is added to standard care[3] Interest Income and Expense - Interest income decreased to $17,610 in 2024 from $122,131 in 2023, a decline of about 86%[21] - Interest expense increased significantly to $(92,475) in 2024 from $(37,125) in 2023, representing an increase of approximately 149%[21] Shareholder Information - Weighted average common shares outstanding increased to 12,125,029 in 2024 from 8,747,509 in 2023, a rise of about 39%[21]

Group 1 - bioAffinity Technologies, Inc. has closed warrant exercise agreements with four accredited investors, resulting in the exercise of 2,438,473 shares of common stock for gross cash proceeds of approximately $1.4 million [1][2] - In exchange for the immediate exercise of existing warrants, the investors will receive new unregistered warrants to purchase up to 2,926,166 shares of common stock at an exercise price of $0.85 per share, which is 120% of the shares issued from the existing warrants [1] - The exercise price of the existing warrants has been reduced from $1.50 to $0.58 per share as part of this transaction [1] Group 2 - WallachBeth Capital is acting as the sole placement agent for the warrant inducement transaction [2] - The gross proceeds from the warrant inducement are expected to be approximately $1.4 million, excluding any proceeds from the exercise of the new warrants and before deducting placement agent fees and other offering expenses [2]

Group 1 - WallachBeth Capital LLC announced that bioAffinity Technologies, Inc. has entered into warrant exercise agreements with three accredited investors to exercise existing warrants for a total of 2,438,473 shares of common stock, generating approximately $1.4 million in gross cash proceeds [1][2] - In exchange for the immediate exercise of the existing warrants, the investors will receive new unregistered warrants to purchase up to 2,926,168 shares of common stock at an exercise price of $0.85 per share, which is 120% of the shares issued from the existing warrants [1] - The exercise price of the existing warrants has been reduced from $1.50 to $0.58 per share as part of this agreement [1] Group 2 - The closing of the offering is expected to occur on or about February 26, 2025, pending customary closing conditions [2] - WallachBeth Capital is acting as the sole placement agent for this warrant inducement transaction [2]